In this large‐scale retrospective analysis of 1053 patients with ALK‐positive NSCLC, we showed that decreases in HR are common with the use of crizotinib, with a mean observed decrease of approximately 25 bpm among all evaluated patients. The gene discussed is ALK; the disease is non-small cell lung carcinoma.